Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas

Journal of Thoracic Oncology

Volumn 4, Issue 10, 2009, Pages 1270-1273

  Giaccone, Giuseppe ^a,b   Rajan, Arun ^b   Ruijter, Rita ^a   Smit, Egbert ^a   Van Groeningen, Cees ^a   Hogendoorn, Pancras C W ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Imatinib; KIT; Thymoma.

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; IMATINIB; PEMETREXED; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG TOLERABILITY; EDEMA; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INOPERABLE CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SURVIVAL TIME; THYMOMA; THYMUS CANCER; TREATMENT RESPONSE; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 70349706152     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181b6be57     Document Type: Article

References (16)

1. Schmidt-Wolf IG, Rockstroh JK, Schuller H, et al. Malignant thymoma: current status of classification and multimodality treatment. Ann Hema-tol. 2003;82:69-76.
2. Rosai J. Histological Typing of Tumors of the Thymus. New York, Berlin: Springer-Verlag, 1999.
3. Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas CR Jr. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004;59:654-664.
4. Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004;130:222-224.
5. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202: 375-381.
6. Kantarjian H, Sawyers C, Hochhaus A, et al.; International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
7. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
8. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134.
9. Sciot R, biec-Rychter M, Daugaard S, et al. EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian Trials Group. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): an analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. Eur J Cancer 2008;44:1855-1860.
10. de Leeuw WJ, Dierssen J, Vasen HF, et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol 2000; 192:328-335.
11. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol. 2005;23:49-57. (Pubitemid 41702622)
12. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with over-expression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625-2626.
13. Tsuchida M, Umezu H, Hashimoto T, et al. Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 2008;62:321-325.
14. Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008;62:316-320.
15. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99:734-740.
16. Salter JT, Lewis D, Yannoutsos C, Loehrer PJ, Risley L, Chiorean EG. Imatinib in the treatment of thymic carcinoma. J Clin Oncol 2008;26:452s.